Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.52 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15676710 | 0.90 | KMT2A (0.82) | KMT2AMEN1HSD17B1HSD17B2HDAC1 | |
| SCHEMBL10268085 | 0.89 | KMT2A (0.62) | KMT2AMEN1HSD17B1HSD17B2LIMK2 | |
| SCHEMBL15676756 | 0.87 | KMT2A (0.65) | KMT2AMEN1HSD17B1HSD17B2LIMK2 | |
| SCHEMBL15676750 | 0.87 | KMT2A (0.64) | KMT2AMEN1HSD17B1HSD17B2LIMK2 | |
| SCHEMBL18773850 | 0.87 | KMT2A (0.67) | KMT2AMEN1HSD17B1HSD17B2LIMK2 | |
| SCHEMBL1691687 | 0.85 | KMT2A (0.61) | KMT2AMEN1HSD17B1HSD17B2LIMK2 | |
| SCHEMBL15676804 | 0.85 | KMT2A (0.82) | KMT2AMEN1HSD17B2LIMK2HSP90AA1 | |
| SCHEMBL18970421 | 0.85 | KMT2A (0.61) | KMT2AMEN1HSD17B1HSD17B2LIMK2 | |
| SCHEMBL10268291 | 0.84 | KMT2A (0.64) | KMT2AMEN1HSD17B1HSD17B2ALDH1A1 | |
| SCHEMBL15676803 | 0.84 | KMT2A (0.59) | KMT2AMEN1HSD17B1HSD17B2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-15 | — | — | US | disclosed |
| EP-1773786-B1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9617224-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150259297-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-17 | — | — | US | disclosed |
| US-9079860-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-14 | — | — | US | disclosed |
| US-8716492-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166560-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | KMT2A 2123/4885MEN1 1384/4885HSD17B1 1388/4885 |
| US-20150259297-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | KMT2A 2123/4885MEN1 1384/4885HSD17B1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.